The Groningen Intervention study for the Preservation of cardiac function with STS after STEMI (GIPS-IV) trial is a double-blind, randomized, placebo-controlled, multicenter trial. touchCARDIO speaks with Dr Marie-Sophie de Koning (University of Groningen, Groningen, The Netherlands) to discuss her presentation of the GIPS-IV trial and to highlight the rationale, design, and study findings.
Questions: Marie-Sophie de Koning has nothing to disclose in relation to this video.
- What is the rationale for the use of hydrogen sulphide in patients after ST-segment Elevation Myocardial Infarction (STEMI)? (00:19)
- What are the aims and design of the GIPS-IV trial? (01:05)
- What are the clinical endpoints and eligibility findings of the study? (02:08)
- What are the study findings to date? (02:38)
Disclosures: Marie-Sophie de Koning has nothing to disclose in relation to this video.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Shanice Allen.
Filmed in coverage of the American College of Cardiology Annual Meeting 2022
